A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects

• Status: Completed
• Trial end date: 2024-02-20
• Target enrollment: 0
• Participant gender: All

Summary

This is a phase I study to evaluate drug-drug interactions (DDIs) of JAB-21822 as a perpetrator combined with midazolam , rosuvastatin, and digoxin and to evaluate DDIs of JAB-21822 as a victim combined with itraconazole， rifampicin， and omeprazole in healthy subjects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Jacobio Pharmaceuticals Co., Ltd.
• Treatments: Calcium; Digoxin; Itraconazole; Midazolam; Omeprazole; Rifampin; Rosuvastatin Calcium

Criteria

Inclusion Criteria:

1. Male or female ；Healthy subjects aged 18 to 50 years (including both ends) at the time of signing informed consent

2. Male subjects weighed ≥50kg, female subjects weighed ≥45kg, body mass index (BMI) was between 19.0 and 26.0kg/m2, BMI= weight (kg)/height 2 (m2), including boundary values.

3. Subjects voluntarily signed written informed consent and were able to communicate well with the investigator

Exclusion Criteria:

1. History of severe systemic diseases, history of liver and kidney insufficiency, history of mental illness, history of drug dependence;

2. Patients with a history of interstitial pneumonia, pulmonary fibrosis or other interstitial lung diseases who were not eligible for admission by the investigators;

3. Have a history of dysphagia or any gastrointestinal disease that affects drug absorption, and have digestive diseases (such as peptic ulcer, pancreatitis, colitis, etc.) within 3 months before the first dose;

4. The investigator believes that the subject has any other circumstances that make him or her unfit to participate in this clinical trial